查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790438

美國制酸劑市場規模、佔有率和趨勢分析報告，按類型、最終用途、主要企業、競爭分析和細分預測，2025-2030 年

U.S. Antacids Market Size, Share & Trends Analysis Report By Type (Tablet, Liquid, Others), By End-use (Retail Pharmacy, Hospital Pharmacy, Others), Key Companies, Competitive Analysis, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國制酸劑市場摘要

美國制酸劑市場預計在 2024 年價值 30 億美元，預計到 2030 年將達到 37.3 億美元，2025 年至 2030 年的複合年成長率為 3.7%。飲食習慣的改變是預測期內推動市場成長的關鍵因素。

胃食道逆流症 (GERD)、消化性潰瘍以及其他導致胃酸過多、消化不良和胃灼熱等消化器官系統疾病的病例不斷增加，預計也將推動市場擴張。根據美國疾病管制與預防中心 (CDC) 2024 年 12 月發布的報告，約有 5.9% 的美國成年人被診斷出患有潰瘍。其他關鍵促進因素包括人們對非處方 (OTC)制酸劑的認知不斷提高以及其供應量不斷增加，這些藥物可以快速有效地緩解症狀。

此外，壓力、吸煙、飲酒、不良飲食和肥胖等生活習慣會導致酸相關症狀，預計將進一步影響美國制酸劑產業的發展。例如，美國疾病管制與預防中心 (CDC) 於 2024 年 9 月發布的一份報告發現，2021 年 8 月至 2023 年 8 月期間，美國成年人的肥胖盛行率為 40.3%，其中 40-59 歲年齡層和教育程度較低的人口盛行率最高。重度肥胖影響 9.4% 的成年人，且在所有年齡層中，女性的盛行率均高於男性。

大多數產品開發都集中在咀嚼錠、液體、即溶片、品牌等給藥形式。預計適度創新將來自組合配方和非處方益生菌混合配方，這些配方有望推動美國制酸劑行業的需求。

美國制酸劑市場受到嚴格監管，尤其因為制酸劑屬於非處方藥 (OTC)。 FDA 會監控其配方、標籤和市場宣傳，以確保其安全性和有效性。新配方和組合藥物必須符合特定的 OTC 專論標準，而某些成分（例如雷尼替丁）已因安全問題被撤回。這意味著製造商必須不斷適應不斷變化的監管準則，尤其是在產品安全、召回和透明度方面。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國制酸劑市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國制酸劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 美國制酸劑市場：通路分析

第4章美國制酸劑市場：類型估計和趨勢分析

  • 類型細分儀表板
  • 美國制酸劑市場：類型變化分析
  • 美國制酸劑市場規模及趨勢分析（2018-2030）
  • 錠劑
  • 液體
  • 其他

第5章美國制酸劑市場：最終用途估計與趨勢分析

  • 最終用途細分儀表板
  • 美國制酸劑市場：最終用途差異分析
  • 美國制酸劑市場規模及最終用途趨勢分析（2018-2030）
  • 醫院藥房
  • 零售藥局
  • 其他

第6章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key company heat map analysis, 2024
  • 公司簡介
    • Haleon Group of Companies.
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Sanofi
    • Reckitt Benckiser Group plc
    • Sun Pharmaceuticals Ltd.
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Procter &Gamble
Product Code: GVR-4-68040-666-9

U.S. Antacids Market Summary

The U.S. antacids market size was estimated at USD 3.00 billion in 2024 and is projected to reach USD 3.73 billion in 2030, growing at a CAGR of 3.7% from 2025 to 2030. Changing dietary habits is a key factor propelling market growth over the forecast period.

Rising cases of digestive issues such as gastroesophageal reflux disease (GERD), peptic ulcers, and other stomach problems that cause acidity, indigestion, and heartburn are also expected to support market expansion. According to a report published by the CDC in December 2024, approximately 5.9% U.S. adults were diagnosed with ulcers. Other key drivers include rising awareness and easy access to over-the-counter (OTC) antacids, which provide fast and effective relief from symptoms.

In addition, lifestyle factors such as stress, smoking, alcohol use, poor diet, and obesity, all of which contribute to acid-related conditions, are expected to further influence the growth of the U.S. antacid industry. For instance, according to a report by the CDC published in September 2024, the prevalence of obesity was 40.3% among adults in the U.S. from August 2021 to August 2023. The highest rates are seen in adults aged 40-59 and those with lower education levels. Severe obesity affected 9.4% of adults, with women showing higher rates than men across all age groups.

Most product development focuses on delivery formats such as chewable, liquids, fast-dissolve tablets, and branding. Some moderate innovation comes from combo formulations or OTC-probiotic hybrids which are expected to drive the demand for U.S. antacid industry.

The U.S. antacid market is subject to the high impact of regulations, particularly because antacids are available over-the-counter (OTC). The FDA monitors formulation, labeling, and marketing claims to ensure safety and efficacy. New formulations or combinations must meet specific OTC monograph standards, and some ingredients, such as ranitidine, have been withdrawn due to safety concerns. This means manufacturers must continuously adapt to evolving regulatory guidelines, especially around product safety, recalls, and transparency.

U.S. Antacids Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. antacid market on the basis of types, and end-use:

  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Tablet
  • Liquid
  • Others
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. End use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Antacid Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Antacid Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. U.S. Antacid Market: Pipeline Analysis

Chapter 4. U.S. Antacid Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. Antacid Market: Type Movement Analysis
  • 4.3. U.S. Antacid Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Tablet
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Liquid
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Antacid Market: End use Estimates & Trend Analysis

  • 5.1. End use Segment Dashboard
  • 5.2. U.S. Antacid Market: End use Movement Analysis
  • 5.3. U.S. Antacid Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacy
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Retail Pharmacy
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Key company heat map analysis, 2024
  • 6.4. Company Profiles
    • 6.4.1. Haleon Group of Companies.
      • 6.4.1.1. Company overview
      • 6.4.1.2. Financial performance
      • 6.4.1.3. Type benchmarking
      • 6.4.1.4. Strategic initiatives
    • 6.4.2. Bayer AG
      • 6.4.2.1. Company overview
      • 6.4.2.2. Financial performance
      • 6.4.2.3. Type benchmarking
      • 6.4.2.4. Strategic initiatives
    • 6.4.3. Boehringer Ingelheim International GmbH
      • 6.4.3.1. Company overview
      • 6.4.3.2. Financial performance
      • 6.4.3.3. Type benchmarking
      • 6.4.3.4. Strategic initiatives
    • 6.4.4. Dr. Reddy's Laboratories Ltd.
      • 6.4.4.1. Company overview
      • 6.4.4.2. Financial performance
      • 6.4.4.3. Type benchmarking
      • 6.4.4.4. Strategic initiatives
    • 6.4.5. Sanofi
      • 6.4.5.1. Company overview
      • 6.4.5.2. Financial performance
      • 6.4.5.3. Type benchmarking
      • 6.4.5.4. Strategic initiatives
    • 6.4.6. Reckitt Benckiser Group plc
      • 6.4.6.1. Company overview
      • 6.4.6.2. Financial performance
      • 6.4.6.3. Type benchmarking
      • 6.4.6.4. Strategic initiatives
    • 6.4.7. Sun Pharmaceuticals Ltd.
      • 6.4.7.1. Company overview
      • 6.4.7.2. Financial performance
      • 6.4.7.3. Type benchmarking
      • 6.4.7.4. Strategic initiatives
    • 6.4.8. Takeda Pharmaceutical Company Limited
      • 6.4.8.1. Company overview
      • 6.4.8.2. Financial performance
      • 6.4.8.3. Type benchmarking
      • 6.4.8.4. Strategic initiatives
    • 6.4.9. Pfizer Inc.
      • 6.4.9.1. Company overview
      • 6.4.9.2. Financial performance
      • 6.4.9.3. Type benchmarking
      • 6.4.9.4. Strategic initiatives
    • 6.4.10. Procter & Gamble
      • 6.4.10.1. Company overview
      • 6.4.10.2. Financial performance
      • 6.4.10.3. Type benchmarking
      • 6.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. antacid market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. antacid market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. antacid market: market outlook
  • Fig. 10 U.S. antacid competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. antacid market driver impact
  • Fig. 16 U.S. antacid market restraint impact
  • Fig. 17 U.S. antacid market strategic initiatives analysis
  • Fig. 18 U.S. antacid market: Type movement analysis
  • Fig. 19 U.S. antacid market: Type outlook and key takeaways
  • Fig. 20 Tablet market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Liquid market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. antacid Market: End use movement Analysis
  • Fig. 24 U.S. antacid market: End use outlook and key takeaways
  • Fig. 25 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Retail pharmacy market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts,2018 - 2030 (USD Million)